<DOC>
	<DOCNO>NCT02022501</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , bioactivity pharmacokinetics three concentration DE-120 single intravitreal injection subject late stage exudative age-related macular degeneration .</brief_summary>
	<brief_title>A Phase I/II Safety Study DE-120 Injectable Solution Age-related Macular Degeneration</brief_title>
	<detailed_description>This open-label , dose-escalating , sequential-cohort study DE-120 injectable solution administer 9 , 12 , subject late stage exudative age-related macular degeneration . Three cohort 3 subject receive single intravitreal injection study eye . Subjects Cohort 1 receive single intravitreal injection Low Dose DE-120 injectable solution study eye evaluate Visit 5 ( Month 1 ) . If Low Dose consider safe , next high dose administer Cohort 2 . The enrollment safety review procedure follow Cohort 2 ( Medium Dose DE-120 ) Cohort 3 ( High Dose DE-120 ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Main Understand provide sign write informed consent Diagnosis chronic subretinal intraretinal fluid secondary exudative agerelated macular degeneration study eye At least one lesion study eye meet minimal pathology criterion Visual acuity â‰¤ 55 ETDRS letter ( 20/80 Snellen equivalent ) bad study eye , exclude No Light Perception Reasonably clear medium fixation study eye Main Ocular Visual acuity No Light Perception Aphakic anterior chamber intraocular lens study eye . Use anticipated use intravitreal , periocular photodynamic therapy study eye treatment AMD within specify timeframe prior Visit 1 Uncontrolled glaucoma , chronic hypotony vitrectomy study eye Evidence ocular disease late stage exudative age relate macular degeneration study eye may confound outcome study . Proscribed ocular surgery study eye either prior course trial Presence history certain ocular periocular pathology condition could limit ability perform require study assessment either eye and/or confound study result NonOcular Systemic treatment antiVEGF agent ( e.g. , bevacizumab ) prohibit time study Allergy hypersensitivity study drug product , fluorescein dye , study related procedures/medications . Current history certain systemic condition , abnormality therapy would render subject poor candidate clinical trial Participation investigational drug device clinical trial within 30 day prior Screening plan participate investigational drug device clinical trial duration study Females pregnant lactating female childbearing potential use adequate contraceptive precaution men agree practice acceptable method contraception throughout course study Unable comply study procedure followup visit</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Macular Degeneration</keyword>
</DOC>